
ROCHESTER Minn. – Mayo Clinic today announced that fundraising associated with the VICE documentary “Killing Cancer,” which aired on HBO earlier this year, has exceeded $2 million. This achievement was reached a month earlier than anticipated. The Killing Cancer campaign also set a record at Mayo Clinic with 30 percent of gifts received online, compared to 10 percent for previous campaigns. Many of the gifts came from new supporters to Mayo Clinic a reflection the younger demographics of the VICE audience and VICE’s strong digital presence. “The money raised in the Killing Cancer campaign will have impact right away, helping advance cancer research and finding cures for patients,” said John Noseworthy, M.D., Mayo Clinic president and CEO. The success of the campaign was due in large part to a fundraising match challenge issued by VICE founder and CEO Shane Smith with a total goal of $2 million. Through the challenge, Mr. Smith matched the first $1 million in gifts made by more than 10,000 documentary viewers and loyal Mayo Clinic supporters. MEDIA CONTACT: Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu
Mayo Clinic Researcher Explains Five Individual Categories for Treatment of Obesity https://www.youtube.com/watch?v=4Sc_Q4ls6uk ROCHESTER, Minn. – Mayo Clinic researchers have identified five sub-categories of obesity in an effort to determine the most effective, individual treatments. More than two in three adults are considered to be overweight or obese and 17 percent of children are obese in the United States. Obesity is a costly health issue that increases the risk for heart disease, type 2 diabetes, and cancer, among others. The prevalence of obesity continues to rise despite education and efforts around diet, exercise, and drug/surgical therapy. In response, researchers asked how the gastrointestinal system affects obesity. MEDIA CONTACT: Brian Kilen, Mayo Clinic Public Affairs, 507-284-5005 or newsbureau@mayo.edu
JACKSONVILLE, Fla. — Researchers at Mayo Clinic in Florida have developed a mouse model that exhibits the neuropathological and behavioral features associated with the most common genetic form of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and frontotemporal dementia (FTD), which are caused by a mutation in the C9ORF72 gene. They say their findings, reported today in Science, will speed further research into the molecular mechanism behind these disorders and that the animal model will offer a way to test potential therapeutic agents to halt the death of neurons in the brain and spinal cord. MEDIA CONTACT: Kevin Punsky, Mayo Clinic Public Affairs, 904-953-0746, punsky.kevin@mayo.edu Journalists: Sound bites with Dr. Petrucelli are available in the downloads. https://www.youtube.com/watch?v=ICxKfCy_m2c
ROCHESTER, Minn. -- Mayo Clinic, in collaboration with Baylor College of Medicine, is planning to launch a study of 10,000 Mayo biobank members for potential risk of drug reactions or lack of drug effect based on each individual’s genome. Researchers will be sequencing the DNA of the biobank members for 69 different genes that can influence how patients’ metabolize or react to different drugs. The goal is to determine which “pharmacogenomic” findings are relevant to that individual patient and to insert that information into their medical records – providing an “early warning system” to prevent adverse drug reactions or ineffective treatments. “This is a huge step toward bringing knowledge of pharmacogenomics into patient care,” says Richard Weinshilboum, M.D., Pharmacogenomics Program Director at Mayo Clinic’s Center for Individualized Medicine and the Mary Lou and John H. Dasburg Professor of Cancer Genomics. “Most importantly, it has the potential of preventing errors and identifying the most appropriate drugs and individualized treatments for thousands of patients – thanks to research on the human genome.” Media Contact: Bob Nellis at Mayo Clinic Public Affairs: 507-284-5005 or newsbureau@mayo.edu
An online patient support community